Displaying drugs 876 - 900 of 1421 in total
CG0070
CG0070 is investigated in clinical trials for treating bladder cancer. CG0070 is a solid. CG0070 can potentially destroy cancer cells by two different mechanisms: direct cell killing by the virus and immune-mediated cell killing stimulated by GM-CSF. CG0070, an oncolytic virus therapy with specificity for multiple cancers, has been evaluated...
Investigational
PF-03187207
PF-03187207 is a nitric oxide-donating prostaglandin F2-alpha analogs for the potential treatment of glaucoma. Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP. The development of abnormally high IOP, due to blockage...
Investigational
BIIB015
BIIB015 is a humanized, IgG1 [immunoglobulin G 1], DM4-Conjugated, anti-cripto, monoclonal antibody. It has been investigated for the treatment of subjects with relapsed or refractory solid tumours.
Investigational
PF-00489791
PF-00489791 has been used in trials studying the treatment of Hypertension, Raynaud's Disease, Diabetic Nephropathies, Hypertension, Pulmonary, and Peripheral Vascular Disease.
Investigational
PF-04418948
Pf 04418948 is under investigation in clinical trial NCT01002963 (A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy Volunteers).
Investigational
PF-03715455
PF-03715455 has been used in trials studying the treatment of Asthma, Pulmonary Disease, Chronic Obstructive, and Chronic Obstructive Pulmonary Disease (COPD).
Investigational
PF-00446687
PF-00446687 has been investigated for the treatment of Erectile Dysfunction.
Investigational
PF-04995274
Pf 04995274 is under investigation in clinical trial NCT01193062 (Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274).
Investigational
PF-03382792
Pf 03382792 is under investigation in clinical trial NCT01045863 (To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers).
Investigational
PF-03814735
PF-03814735 has been used in trials studying the treatment of Solid Tumors.
Investigational
PF-06459988
PF-06459988 is under investigation in clinical trial NCT02297425 (A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer).
Investigational
PF-06815345
PF-06815345 is under investigation in clinical trial NCT02654899 (Single Dose Study of PF-06815345 in Healthy Subjects).
Investigational
PF-04620110
PF-04620110 is under investigation in clinical trial NCT01146327 (A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects).
Investigational
PF-04634817
PF-04634817 is under investigation in clinical trial NCT01140672 (A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects).
Investigational
PF-06700841
PF-06700841 is under investigation in clinical trial NCT03236493 (Safety and Pharmacokinetic Study of PF-06700841 in Japanese Healthy Volunteers).
Investigational
PF-05105679
PF-05105679 is under investigation in clinical trial NCT01393652 (Single Dose, Dose Escalation Healthy Volunteers Study Of PF-05105679).
Investigational
PF-05212377
PF-05212377 is under investigation in clinical trial NCT01712074 (Study Evaluating Thesafety and Efficacy of PF-05212377 or Placebo in Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms on Donepezil).
Investigational
GS030-DP
GS030-DP is an optogenetic gene therapy being investigated for the treatment of retinitis pigmentosa. It targets retinal ganglion cells that encodes a light-sensitive channelrhodopsin, ChrimsonR-tdTomato (ChR-tdT), delivered by an AAV2.7m8 vector. It is a component of GS030, an investigational optogenetic treatment, in combination with a medical device GS030-MD.[A259816, L46701]
Investigational
PF-06842874
Investigational
CTA018
CTA018 is a member of a new class of vitamin D analogues with a dual mechanism of action, called Vitamin D Signal Amplifiers. This proprietary new drug is both a potent inhibitor of CYP24 (the enzyme responsible for the breakdown of vitamin D) and a potent activator of vitamin D...
Investigational
trans NV-04
trans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial stiffness.
Investigational
MAHDL01
MAHDL01 is a pharmaceutical combination of whole plants, which is used to increase the HDL/LDL ratio that improves overall cardiovascular health.
Investigational
DAR-0100A
DAR-0100A is under investigation in clinical trial NCT01466205 (Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder).
Investigational
GTA002
Investigational
Displaying drugs 876 - 900 of 1421 in total